Typical vial
2 mg
Common dose
0.2 mg
Frequency
7×/week
Half-life
—
Calculate CJC-1295 reconstitution
Open the free calculator pre-filled with CJC-1295 values — no account needed.
Dosing & Protocol Overview
Research Notes
Frequently studied with Ipamorelin in research; timing depends on study design.
How Reconstitution Works
Reconstitution is the process of mixing a lyophilized (freeze-dried) peptide powder with bacteriostatic water to create an injectable solution. The concentration depends on how much BAC water you add to the vial.
For a 2 mg vial of CJC-1295, the calculator works out the mg/ml concentration based on your BAC water volume, then converts your target dose (0.2 mg) into the exact number of units to draw on an insulin syringe.
Try it now — pre-filled for CJC-1295Track Your CJC-1295 Protocol
Once you've calculated your reconstitution, ReconDose lets you log every injection, build a dosing schedule, track side effects, and record biomarkers — all in one place. Create a free account to get started.
Research & References
The following publicly available studies are provided for research and educational purposes only. They are not medical advice. Click through to read the original publications.
Teichman SL, et al. · Journal of Clinical Endocrinology & Metabolism · 2006
Two randomized, placebo-controlled, double-blind ascending dose trials. Single CJC-1295 injection produced dose-dependent 2-10x GH increases for 6+ days and 1.5-3x IGF-I increases for 9-11 days. Estimated half-life 5.8-8.1 days. Safe and well tolerated at 30-60 µg/kg.
Iglesias J, et al. · Journal of Clinical Endocrinology & Metabolism · 2006
Assessed GH pulsatility after 60 or 90 µg/kg CJC-1295 in healthy men. GH pulsatility was preserved. Basal (trough) GH levels increased 7.5-fold. Mean GH increased 46% and IGF-I increased 45%. Demonstrates CJC-1295 enhances trough GH while maintaining physiological pulsatility.
Jette L, et al. · Endocrinology · 2005
Original characterization of CJC-1295 as a tetrasubstituted hGRF(1-29) analog with drug affinity complex (DAC) technology. Showed 4-fold increase in GH AUC vs hGRF(1-29) in rats. CJC-1295 remained in plasma beyond 72 hours via albumin binding. Foundational pharmacokinetic study.
Have a study we should add? Let us know. See our research hub for more studies and the Khavinson peptide bioregulator collection.